Results 51 to 60 of about 17,756 (247)

Expression and significance of dendritic cell markers CD123, FXⅢA and CD1a in leprosy lesions

Pifu-xingbing zhenliaoxue zazhi, 2021
Objective: To explore the role of dendritic cells in the pathogenesis of leprosy. Method: The expression of three dendritic cell markers (CD123, FXⅢA, CD1a) in leprosy lesions was assessed by immunohistochemical staining, and their significance was ...
Wenjun ZHOU, Yan QIN
doaj   +1 more source

CD123 expression levels in 846 acute leukemia patients based on standardized immunophenotyping [PDF]

, 2018
Background: While it is known that CD123 is normally strongly expressed on plasmacytoid dendritic cells and completely absent on nucleated red blood cells, detailed information regarding CD123 expression in acute leukemia is scarce and, if available ...
Velden, V.H.J. (Vincent) van der, Haas, V. (Valerie) de, Zwaan, C.M. (Michel), Jongen-Lavrencic, M. (Mojca), Beverloo, H.B. (Berna), Dongen, J.J.M. (Jacques) van, Marvelde, J.G. (Jeroen) te, Bras, A.E. (Anne), van Stigt, A. (Arthur), Leusen, R. (Robert) van   +9 more
core   +1 more source

The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS

Nature Communications
Strategies targeting leukemic stem and progenitor cells (LSPCs) are needed for durable remissions in acute myeloid leukemia (AML) and high-risk myelodysplastic neoplasms (MDS).
N. Schmitt, Jana Siegler, Alexandra Beck, Thomas H. Müller, I. Kozlowska, S. Sarlang, Uwe Reusch, S. Knackmuss, J. Medina-Echeverz, Joachim Koch, T. Ross, A. Darwich, Lea Hoppe, M. Abba, A. Streuer, Stefan Klein, W. Hofmann, Anna Lisa Gündner, C. Merz, J. Endell, J. Pahl, D. Nowak   +21 more
semanticscholar   +1 more source

Current status and future potential of CD123-based targeted therapies for acute leukemia

Expert Opinion on Biological Therapy
Introduction Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and blastic plasmacytoid dendritic cell neoplasm (BPDCN) are aggressive hematologic malignancies with poor outcomes, particularly in relapsed/refractory settings.
Shukaib Arslan, A. Aribi, A. Stein, I. Aldoss   +3 more
semanticscholar   +1 more source

IMMUNOPHENOTYPIC COMPARISON BETWEEN REACTIVE BONE MARROW B-LYMPHOCYTE PRECURSOR (HEMATOGONES) AND B-NEOPLASTIC LYMPHOBLAST LEUKAEMIA USING CD 34, CD 123 BY FLOWCYTOMETRY

The Iraqi Journal of Medical Sciences, 2016
Background:Flow cytometric study found that lymphoblasts of B acute lymphoblastic leukemia exhibited multiple aberrant antigens by which they can be distinguished from hematogones. These antigens are CD34 and CD123.
Yousra A. Shallan, Raad J. Musa
doaj   +4 more sources

Evaluation of CD96 and CD123 in CD34+ leukemic stem cells in acute myeloid leukemia patients and their relation to response to induction therapy

Iraqi Journal of Hematology, 2016
Background: Leukemic stem cells (LSCs) are thought to originate either from normal hematopoietic stem cells or from more differentiated progenitor cells.
Haidar H Al-Fatlawi, Raad Jaber Musa
doaj   +1 more source

Acute Myeloid Leukemia With Florid Plasmacytoid Dendritic Cell Expansion and Aberrant Expression of CD19. [PDF]

Int J Lab Hematol
International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 919-920, October 2026.
Shameli A, Dorer RK.
europepmc   +2 more sources

Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile

Blood Advances
Key Points • CD33/CD123 NANOBODY TCE kills single and double-positive cells, outperforming single-targeting TCE in a subset of AML samples.• CD33/CD123-TCE efficiently kills AML cells in a mouse model and targets cells in nonhuman primates without signs ...
Z. Zeng, Annelies Roobrouck, Geert Deschamps, Hélène Bonnevaux, Stéphane Guerif, V. D. De Brabandere, Céline Amara, Eline Dejonckheere, A. Virone-Oddos, M. Chiron, Marina Y. Konopleva, Melissa Dullaers   +11 more
semanticscholar   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Epitope prime editing shields hematopoietic cells from CD123 immunotherapy for acute myeloid leukemia.

Cell Stem Cell
Acute myeloid leukemia (AML) is a malignant cancer characterized by abnormal differentiation of hematopoietic stem and progenitor cells (HSPCs). While chimeric antigen receptor T (CAR-T) cell immunotherapies target AML cells, they often induce severe on ...
Rui-Jin Ji, Guo-Hua Cao, Wei-Qiang Zhao, Mu-Yao Wang, Pan Gao, Yi-Zhou Zhang, Xuebin Wang, Houyuan Qiu, Di-Di Chen, Xiao-Han Tong, Min Duan, Hao Yin, Ying Zhang   +12 more
semanticscholar   +1 more source